Telix Pharmaceuticals Ltd ADR (TLX) — Top EPS Revision Performer
As of 2026-05-05, Telix Pharmaceuticals Ltd ADR (TLX) has a next-year EPS growth estimate of 175.50%. Featured in 1 EPS revision report, most recently on 2026-04-13. Sector: Healthcare.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 175.50%
- EPS growth this year
- 305.04%
- EPS next quarter (est)
- N/A
- Last price
- $11.04
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-05 | 175.50% | 305.04% | N/A | $11.04 |
| 2026-05-04 | 173.92% | 307.09% | N/A | $11.15 |
| 2026-05-03 | 171.73% | 308.37% | N/A | $11.26 |
| 2026-04-30 | 171.73% | 308.37% | N/A | $11.00 |
| 2026-04-29 | 173.27% | 306.33% | $0.02 | $10.43 |
| 2026-04-28 | 173.27% | 306.33% | $0.02 | $10.44 |
| 2026-04-27 | 173.27% | 306.33% | $0.02 | $10.40 |
| 2026-04-26 | 173.27% | 306.33% | $0.02 | $10.56 |
| 2026-04-24 | 173.27% | 306.33% | $0.02 | $10.56 |
| 2026-04-23 | 173.27% | 306.33% | $0.02 | $10.19 |
| 2026-04-22 | 173.27% | 306.33% | $0.02 | $10.33 |
| 2026-04-21 | 173.27% | 306.33% | $0.02 | $10.23 |
| 2026-04-20 | 173.27% | 306.33% | $0.02 | $10.73 |
| 2026-04-19 | 173.27% | 306.33% | $0.02 | $10.74 |
| 2026-04-16 | 180.16% | 297.87% | $0.02 | $10.74 |
| 2026-04-15 | 180.16% | 297.87% | $0.02 | $10.66 |
| 2026-04-14 | 184.64% | 290.39% | $0.02 | $10.70 |
| 2026-04-13 | 184.64% | 290.39% | $0.02 | $11.24 |
| 2026-04-12 | 181.44% | 292.09% | $0.02 | $10.54 |
| 2026-04-10 | 181.44% | 292.09% | $0.02 | $10.41 |
| 2026-04-09 | 181.44% | 292.09% | $0.02 | $9.80 |
| 2026-04-08 | 189.75% | N/A | $0.02 | $9.78 |
| 2026-04-07 | 189.75% | N/A | $0.02 | $9.63 |
| 2026-04-06 | 189.75% | N/A | $0.02 | $9.63 |
| 2026-04-05 | 218.80% | N/A | N/A | $9.13 |
| 2026-04-03 | 189.75% | N/A | $0.02 | $9.63 |
| 2026-04-02 | 189.75% | N/A | $0.02 | $9.63 |
| 2026-04-01 | 189.75% | N/A | $0.02 | $9.63 |
| 2026-04-01 | 218.80% | N/A | N/A | $9.57 |
| 2026-04-01 | 218.80% | N/A | N/A | $9.24 |
Reports Featuring TLX
Recent News
- Telix and Regeneron Announce Strategic Radiopharma CollaborationGlobeNewswire
- FDA Accepts NDA for TLX101-Px (Pixclara)GlobeNewswire
EPS revision data sourced from analyst consensus estimates, refreshed daily. Telix Pharmaceuticals Ltd ADR (TLX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports